We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




New Immunoassay Module Launched Doubling Immunochemistry Tests

By LabMedica International staff writers
Posted on 03 Aug 2016
As diagnostic laboratories evolve to meet growing workloads in an increasingly challenging environment, a new immunoassay module offers high value through its flexibility, which allows for the efficient use of existing resources such as space, infrastructure and personnel.

The module is designed for maximum consolidation at a high throughput, continuous operation and, at the same time, it reduces the amount of waste generated, for more environmentally friendly testing and is now available for countries accepting the Conformité Européene (CE) Mark.

The cobas e 801 module (Roche Diagnostics, Basel, Switzerland) almost doubles the currently available immunochemistry testing capacity on the same footprint. More...
The system only requires a low sample volume, offers an extensive assay menu and delivers fast, reliable and consistent patient results across systems. This benefits patients and healthcare professionals by providing the accurate and timely results needed to make the correct treatment decisions.

The cobas e 801 module is the newest member of the cobas 8000 modular analyzer series. It offers more than 100 immunoassays, across a wide range of disease areas. Up to four cobas e 801 modules can be configured in series, delivering up to 1,200 tests per hour across up to 192 reagent positions. The possible turn-around times for routine and emergency samples are the lowest available on the central laboratory market, with 18 minutes for routine and nine minutes for emergency tests, for instance with cardiac markers.

The small sample volumes required for testing are especially beneficial for critical patients, such as neonates and oncology patients. The cobas e 801 module uses the well-established Elecsys technology. The cobas e 801 allows for continuous loading of reagents and consumables and has a high uptime while requiring less hands-on time. Roland Diggelmann, MBA, the CEO Roche Diagnostics, said, “Today, laboratories need to deliver more diagnostic tests than ever before, while in many cases their resources are constrained. The cobas e 801 module is an important part of Roche’s connected laboratory solutions that allows laboratories to test efficiently and to sustainably grow their testing capacity.”

Related Links:
Roche Diagnostics



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Collection and Transport System
PurSafe Plus®
Gold Member
Hematology Analyzer
Medonic M32B
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The genomic test measures eight gene activities in a melanoma tumor and combines this data with patient factors like age and tumor thickness (Photo courtesy of 123RF)

Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients

Accurately determining whether melanoma has spread to the lymph nodes is crucial for guiding treatment decisions, yet the standard procedure—sentinel lymph node biopsy—remains invasive, costly, and unnecessary... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.